INVIVYD, INC.
Last · NasdaqGM$0.6078-0.0382 (-5.91%)close · yahoo · 17h ago
Vol 3.89M ≈ 2.36M
MA10MA20MA50
Market cap$179.15M294.8M sh
P/E · TTM-2.4fwd -1.1 · eps -0.31 · loss
Beta0.95vs S&P 500
Div yield0.00%annual · TTM
52w range
$0.528$3.07
Volume3.9Msession
Issuer
Legal nameINVIVYD, INC.
HQUnited States (US)
ListingUS IVVD
ISINUS00534A1025
SectorHealthcare
IndustryDrugs (Biotechnology)
SIC2836
CurrencyUSD
Entity registrysec:0001832038
CIK0001832038
Websitewww.invivyd.com
Employees122
AddressInvivyd, Inc. 209 Church Street 06510, New Haven
| Revenue | $53.4M |
|---|---|
| Operating income | $-55.6M |
| Net income | $-52.5M |
| Free cash flow | $-58.3M |
| Operating margin | -104.0% |
| Net margin | -98.2% |
| Return on equity | -21.7% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-03-05
From latest 10-K · 2026-03-05
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Sbc Revenue Elevated
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -98.2%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -108.8%
- Sbc Revenue Elevated — SBC/Revenue 21.8%
- Accumulated Deficit High — Accumulated deficit / equity 395%
- Rd Intensity High — R&D/Revenue 71.7%
Upcoming earnings
THU.5NOV
9:00 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.15
Est. revenue
15.0M
Press & signals
- GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Invivyd Appoints Chairman Marc W. Elia as Chief Executive Officer; Approaches Results of VYD2311 studies DECLARATION and LIBERTY
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 61 filings